이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Vera Therapeutics 관리

관리 기준 확인 4/4

Vera Therapeutics' CEO는 Marshall Fordyce, May2016 에 임명되었습니다 의 임기는 8.08 년입니다. 총 연간 보상은 $ 3.43M, 17.1% 로 구성됩니다. 17.1% 급여 및 82.9% 보너스(회사 주식 및 옵션 포함). 는 $ 8.14M 가치에 해당하는 회사 주식의 0.42% 직접 소유합니다. 8.14M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 3.7 년입니다.

주요 정보

Marshall Fordyce

최고 경영자

US$3.4m

총 보상

CEO 급여 비율	17.1%
CEO 임기	8.2yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

CEO 보상 분석

Marshall Fordyce 의 보수는 Vera Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$94m
Dec 31 2023	US$3m	US$586k	-US$96m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$107m
Mar 31 2023	n/a	n/a	-US$102m
Dec 31 2022	US$4m	US$551k	-US$89m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$45m
Dec 31 2021	US$1m	US$479k	-US$33m
Sep 30 2021	n/a	n/a	-US$59m
Jun 30 2021	n/a	n/a	-US$55m
Mar 31 2021	n/a	n/a	-US$56m
Dec 31 2020	US$3m	US$360k	-US$53m

보상 대 시장: Marshall 의 총 보상 ($USD 3.43M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 5.67M ).

보상과 수익: Marshall 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Marshall Fordyce (49 yo)

8.2yrs

테뉴어

US$3,429,733

보상

Dr. Marshall W. Fordyce, M.D. is Founder of Vera Therapeutics, Inc. and has been its President, Chief Executive Officer and Director since May 2016. From April 2011 to July 2016, Dr. Fordyce held a number...

리더십 팀

이름	위치	테뉴어	보상	소유권
Marshall Fordyce	Founder	8.2yrs	US$3.43m	0.42% $ 8.3m
Sean Grant	Chief Financial Officer	3yrs	US$1.76m	0.041% $ 817.2k
Joseph Young	Senior VP of Finance & Chief Accounting Officer	3.2yrs	데이터 없음	0.035% $ 699.4k
Julien Capers	VP & Head of Legal	2.5yrs	데이터 없음	데이터 없음
Kelly Rauber	VP & Head of Human Resources	2.5yrs	데이터 없음	데이터 없음
Tom Doan	Senior Vice President of Development Operations	4.3yrs	데이터 없음	데이터 없음
Lauren Frenz	Chief Business Officer	6.9yrs	데이터 없음	데이터 없음
Neeraj Pakala	Senior VP and Head of Product Development & Manufacturing	1.6yrs	데이터 없음	데이터 없음
Kerry Cooper	Senior Vice President of Medical Affairs	1.2yrs	데이터 없음	데이터 없음
Robert Brenner	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
William Turner	Chief Development Officer	less than a year	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: VERA 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Marshall Fordyce	Founder	8.2yrs	US$3.43m	0.42% $ 8.3m
Maha Katabi	Independent Director	3.8yrs	US$153.63k	0% $ 0
Michael Morrissey	Independent Chairman of the Board	2.2yrs	US$187.13k	0% $ 0
Patrick Gerald Enright	Independent Director	3.8yrs	US$155.63k	0% $ 0
Beth Seidenberg	Independent Director	8.1yrs	US$153.13k	0% $ 0
Scott William Morrison	Independent Director	4.3yrs	US$160.63k	0% $ 0
Andrew Cheng	Independent Director	7.2yrs	US$154.63k	0.032% $ 632.7k
Christy Oliger	Director	less than a year	데이터 없음	0.0055% $ 108.1k
Kimball Hall	Independent Director	2.6yrs	US$152.04k	0% $ 0

3.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: VERA 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.

Vera Therapeutics 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Recent updates

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors

Vera Therapeutics, Inc., Annual General Meeting, May 24, 2022

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

High number of new directors

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts

Independent Chairman of the Board recently bought US$215k worth of stock

Vera Therapeutics, Inc. has completed an IPO in the amount of $47.85 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원